RecruitingNot ApplicableNCT04513028
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
Sponsor
Kelly McMasters
Enrollment
30 participants
Start Date
Nov 3, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is exploring whether adding beta-glucan (a natural supplement found in oats and mushrooms) can improve how well the immunotherapy drug pembrolizumab works in people with advanced melanoma (stage III or IV skin cancer).
**You may be eligible if...**
- You have been diagnosed with stage III or IV melanoma
- You are currently starting or continuing pembrolizumab as a treatment and show no active signs of disease
- You are 18 years or older
- You are able to swallow pills
- You are in good enough health to participate
**You may NOT be eligible if...**
- You have had an allergic reaction to beta-glucan before
- You are currently taking ongoing immune-suppressing medications
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIETARY_SUPPLEMENTBeta-Glucan
500mg (1 capsule) by mouth twice a day for 21 days.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04513028
Related Trials
A Study of VET3-TGI in Patients With Solid Tumors
NCT064448157 locations
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
NCT045621291 location
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
NCT062951591 location
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT0642592611 locations
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
NCT0565531213 locations